These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33862461)

  • 41. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
    Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization.
    Xu L; Ota T
    Adipocyte; 2018; 7(2):121-128. PubMed ID: 29376471
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Huang HC; Chen CJ; Lai YH; Lin YC; Chiou WC; Lu HF; Chen YF; Chen YH; Huang C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33808007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.
    Zhao DM; Li CQ; Sun YM; Fan JY; Wu N; Sun YN; Sun XY
    Endokrynol Pol; 2023; 74(2):190-196. PubMed ID: 37039492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
    Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
    Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway.
    Huang S; Wu B; He Y; Qiu R; Yang T; Wang S; Lei Y; Li H; Zheng F
    Hepatol Commun; 2023 Mar; 7(3):e0045. PubMed ID: 36757426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.
    Day EA; Ford RJ; Lu JH; Lu R; Lundenberg L; Desjardins EM; Green AE; Lally JSV; Schertzer JD; Steinberg GR
    Biochem J; 2020 Jun; 477(12):2347-2361. PubMed ID: 32510137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
    Hawley SA; Ford RJ; Smith BK; Gowans GJ; Mancini SJ; Pitt RD; Day EA; Salt IP; Steinberg GR; Hardie DG
    Diabetes; 2016 Sep; 65(9):2784-94. PubMed ID: 27381369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
    Otsuka H; Yokomizo H; Nakamura S; Izumi Y; Takahashi M; Obara S; Nakao M; Ikeda Y; Sato N; Sakamoto R; Miyachi Y; Miyazawa T; Bamba T; Ogawa Y
    Biochem J; 2022 Feb; 479(3):425-444. PubMed ID: 35048967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genipin alleviates high-fat diet-induced hyperlipidemia and hepatic lipid accumulation in mice via miR-142a-5p/SREBP-1c axis.
    Zhong H; Chen K; Feng M; Shao W; Wu J; Chen K; Liang T; Liu C
    FEBS J; 2018 Feb; 285(3):501-517. PubMed ID: 29197188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
    Nishimiya N; Tajima K; Imajo K; Kameda A; Yoshida E; Togashi Y; Aoki K; Inoue T; Nakajima A; Utsunomiya D; Terauchi Y
    Intern Med; 2021 Nov; 60(21):3391-3399. PubMed ID: 33994437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
    Liu Q; Yu J; Wang L; Tang Y; Zhou Q; Ji S; Wang Y; Santos L; Haeusler RA; Que J; Rajbhandari P; Lei X; Valenti L; Pajvani UB; Qin J; Qiang L
    J Hepatol; 2020 Aug; 73(2):361-370. PubMed ID: 32135178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice.
    Kurtz R; Libby A; Jones BA; Myakala K; Wang X; Lee Y; Knoer G; Lo Cascio JN; McCormack M; Nguyen G; Choos END; Rodriguez O; Rosenberg AZ; Ranjit S; Albanese C; Levi M; Ecelbarger CM; Shepard BD
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
    Watanabe Y; Nakayama K; Taniuchi N; Horai Y; Kuriyama C; Ueta K; Arakawa K; Senbonmatsu T; Shiotani M
    PLoS One; 2015; 10(1):e0116851. PubMed ID: 25615826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.